Published: October 2021
Light activated therapies are considered to be a transformative approach owing to their capability to eradicate diseased cells from the body with minimal side effects; presenting lucrative opportunities for players engaged in the development of such products
Rising prevalence of skin disorders is expected to promote the adoption of light activated therapies, making it one of the relatively faster growing segments of this industry. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in clinical trials registered for such therapy candidates. With multiple therapeutic leads in mid to late development stages (phase II and above), the light activated therapies market is likely to witness significant growth in the foreseen future.
To order this 140+ page report, which features 80+ figures and 120+ tables, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
More than 125 marketed / under development light activated therapies form the current pipeline
At present, 13% of such therapies are marketed, while majority (82%) of the aforementioned candidates are still being evaluated in clinical phases. Examples of approved therapies include Ameluz®, Foscan®, Hemoporfin®, Metvix®, Photofrin® and Sarotalocan®.
Over 485 clinical trials are currently evaluating light activated therapies, worldwide
It is worth mentioning that most of the trials were / are being conducted in North America (34%). More than 28% patients enrolled in trials conducted in the aforementioned region were recruited across different sites in the United States. Further, 69% of the trials are being sponsored by non-industry players.
Over 635 patents have been filed / granted for light activated therapies, since 2018
Over 35% of these intellectual property documents were filed / granted in the North America, with maximum number of patents being filed in US. This is followed by Europe (33%), Asia Pacific and rest of the world (30%).
By 2030, the opportunity within the light activated therapies market is likely to be dominated by the North America
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and likely approval of several advanced stage therapy candidates. Further, Europe and North America (primarily the US) are expected to capture over 80% share of the total market (in terms of sales-based revenues), in 2030.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/light-activated-therapies-market.html
The financial opportunity within the light activated therapies market has been analyzed across the following segments:
The research includes detailed profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), details on product portfolio and recent developments, as well as an informed future outlook.
For additional details, please visit
You may also be interested in the following titles:
1. Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
2. CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
3. Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
6. CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry